Monte Rosa Therapeutics, Inc. (GLUE)

Biological Products, (No Diagnostic Substances) · market cap $1.0B · as of 2026-07-18

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-05 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Monte Rosa Therapeutics (GLUE) is a clinical-stage biotech with 147 employees and a ~$1.96B market cap, developing molecular glue degraders. Its lead asset, oral MRT-2359, is in Phase 2 for non-small cell lung cancer (NSCLC). The company carries $159.9M in cash, implying roughly 12–13 months of runway, and has generated meaningful but non-product revenue (likely partnership/collaboration) alongside persistent net losses.

The catalyst path

2026-11-05 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
Oral MRT-2359	Phase 2	NSCLC

Price & technical context

3-month

-53.5%

6-month

-34.4%

12-month

+52.0%

52-wk range

$7.38–$25.31

vs 50-day MA

-25.2%

vs 200-day MA

-38.2%

Realized vol

81.3%

Max drawdown

-64.3%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for GLUE (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.